| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Immunex Corp., Seattle, WA 98101
Daily treatment of mice with fms-like tyrosine kinase 3 ligand (Flt3L) leads to a significant increase in the number of dendritic cells and induces antitumor immunity. Here, we show that Flt3L and CD40 ligand (CD40L) synergize in the generation of immune responses against two poorly immunogenic tumors, leading to complete tumor rejection in a high proportion of mice. Rechallenge of the Flt3L + CD40L-treated mice with the immunizing tumor resulted in complete inhibition of tumor growth, indicating that these animals had developed long-lasting antitumor immunity. In addition, we demonstrate that endogenous CD40L plays a critical role in antitumor immunity, since blockade of CD40-CD40L interactions in vivo prevents the generation of antitumor immunity in therapeutic and vaccination protocols. Dendritic cells generated in mice treated with Flt3L alone or in combination with CD40L were equally potent in stimulating allogeneic T cells and expressed similar levels of MHC class II, CD80, and CD86. However, mice treated with Flt3L + CD40L had significantly more dendritic cells than mice treated with either of the cytokines alone, suggesting that CD40L promotes the proliferation and/or survival of dendritic cells generated by Flt3L treatment. Dendritic cells generated in this manner are likely to be involved in the priming of antitumor immune responses.
This article has been cited by other articles:
|
|
 |
|
  M. Skarica, T. Wang, E. McCadden, D. Kardian, P. A. Calabresi, D. Small, and K. A. Whartenby Signal Transduction Inhibition of APCs Diminishes Th17 and Th1 Responses in Experimental Autoimmune Encephalomyelitis J. Immunol., April 1, 2009; 182(7): 4192 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. King, A.K.M. G. Muhammad, J. F. Curtin, C. Barcia, M. Puntel, C. Liu, S. B. Honig, M. Candolfi, S. Mondkar, P. R. Lowenstein, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model Neuro-oncol, February 1, 2008; 10(1): 19 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Whartenby, P. A. Calabresi, E. McCadden, B. Nguyen, D. Kardian, T. Wang, C. Mosse, D. M. Pardoll, and D. Small Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease PNAS, November 15, 2005; 102(46): 16741 - 16746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer J. Exp. Med., June 20, 2005; 201(12): 1973 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Teleshova, J. Jones, J. Kenney, J. Purcell, R. Bohm, A. Gettie, and M. Pope Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells J. Leukoc. Biol., June 1, 2004; 75(6): 1102 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and D. H. Lynch 4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner J. Immunol., August 15, 2002; 169(4): 1792 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O'Keeffe, H. Hochrein, D. Vremec, J. Pooley, R. Evans, S. Woulfe, and K. Shortman Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice Blood, March 15, 2002; 99(6): 2122 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance J. Exp. Med., February 11, 2002; 195(4): 423 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Adachi, S. Taketani, J. Toki, K. Ikebukuro, K. Sugiura, H. Oyaizu, R. Yasumizu, M. Tomita, H. Kaneda, Y. Amoh, et al. Marked Increase in Number of Dendritic Cells in Autoimmune-Prone (NZW x BXSB)F1 Mice with Age Stem Cells, January 1, 2002; 20(1): 61 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Vonderheide, J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, et al. Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients J. Clin. Oncol., July 1, 2001; 19(13): 3280 - 3287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Candido, K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents Cancer Res., January 1, 2001; 61(1): 228 - 236. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Morse, S. Nair, M. Fernandez-Casal, Y. Deng, M. St Peter, R. Williams, A. Hobeika, P. Mosca, T. Clay, R. I. Cumming, et al. Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3883 - 3893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Drake III, J. M. Moser, A. Hadley, J. D. Altman, C. Maliszewski, E. Butz, and A. E. Lukacher Polyomavirus-Infected Dendritic Cells Induce Antiviral CD8+ T Lymphocytes J. Virol., May 1, 2000; 74(9): 4093 - 4101. [Abstract] [Full Text]
|
|
|
|
|
|
A. Wang, S. E. Braun, G. Sonpavde, and K. Cornetta Antileukemic Activity of Flt3 Ligand in Murine Leukemia Cancer Res., April 1, 2000; 60(7): 1895 - 1900. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
